About crinetics pharmaceuticals inc - CRNX
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
CRNX At a Glance
Crinetics Pharmaceuticals, Inc.
6055 Lusk Boulevard
San Diego, California 92121
| Phone | 1-858-450-6464 | Revenue | 7.70M | |
| Industry | Pharmaceuticals: Major | Net Income | -465,317,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 640.712% | |
| Fiscal Year-end | 12 / 2026 | Employees | 594 | |
| View SEC Filings |
CRNX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 568.913 |
| Price to Book Ratio | 4.485 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.627 |
| Enterprise Value to Sales | 441.659 |
| Total Debt to Enterprise Value | 0.014 |
CRNX Efficiency
| Revenue/Employee | 12,956.229 |
| Income Per Employee | -783,361.953 |
| Receivables Turnover | 13.00 |
| Total Asset Turnover | 0.005 |
CRNX Liquidity
| Current Ratio | 12.323 |
| Quick Ratio | 12.299 |
| Cash Ratio | 12.083 |
CRNX Profitability
| Gross Margin | 35.473 |
| Operating Margin | -6,714.774 |
| Pretax Margin | -6,043.88 |
| Net Margin | -6,046.219 |
| Return on Assets | -32.521 |
| Return on Equity | -40.167 |
| Return on Total Capital | -44.715 |
| Return on Invested Capital | -38.72 |
CRNX Capital Structure
| Total Debt to Total Equity | 4.893 |
| Total Debt to Total Capital | 4.665 |
| Total Debt to Total Assets | 4.275 |
| Long-Term Debt to Equity | 4.239 |
| Long-Term Debt to Total Capital | 4.041 |